Overview

Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )

Status:
Completed
Trial end date:
2018-08-28
Target enrollment:
Participant gender:
Summary
This Phase I pilot study will evaluate the safety, and tolerability of darTreg infusion for adult, de novo, living donor renal transplant recipients.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Seventh Framework Programme